Collaborations
Our business development team create out-of-the box solutions
Request Our Company Deck
Celularity is fundamentally altering how we approach the treatment of cancer and infectious & degenerative diseases through continuous, innovative application of new discoveries in cellular medicine.
– John Haines, Chief Operating Officer
A fully integrated, purpose-built manufacturing, translational research and biobanking center located in Florham Park, NJ
Our purpose-built, state-of-the-art cGMP-ready manufacturing facility is a 150,000 square foot center that includes nine Grade C/ISO-7 and five Grade B/ISO-9 manufacturing suites designed for commercial production of cellular therapies and advanced biomaterials.
Opportunities
PLATFORM CELL SOURCE
Nature’s immunotherapy engine—the placenta. We are leading the next evolution of cellular medicine with placental-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases.
SCALABLE MANUFACTURING
Our purpose-built, state-of-the-art cGMP-ready manufacturing facility is a 150,000 square foot center that includes nine Grade C/ISO-7 and five Grade B/ISO-9 manufacturing suites designed for commercial production of cellular therapies and advanced biomaterials.
INNOVATION INVESTMENTS
We invest in breakthrough and disruptive innovation to expand freedom to operate across the enterprise, to create stickiness with our clinical partners, and to optimize production processes that allow us to fully monetize our placental supply chain.
Business Development Team
Industry Experts
Celularity is uniquely positioned to drive the development and commercial success of cellular medicine.
PLATFORM CELL SOURCE
Nature’s immunotherapy engine—the placenta. We are leading the next evolution of cellular medicine with placental-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases.
SCALABLE MANUFACTURING
Our purpose-built, state-of-the-art cGMP-ready manufacturing facility is a 150,000 square foot center that includes nine Grade C/ISO-7 and five Grade B/ISO-9 manufacturing suites designed for commercial production of cellular therapies and advanced biomaterials.
INNOVATION INVESTMENTS
We invest in breakthrough and disruptive innovation to expand freedom to operate across the enterprise, to create stickiness with our clinical partners, and to optimize production processes that allow us to fully monetize our placental supply chain.